- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01132417
In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Phase Definition: Phase of investigation, as defined by the US FDA for trials involving investigational new drugs. Select only one.
N/A: for trials without phases Observational Study Design Case-control: group of individuals with specific characteristics (e.g., conditions or exposures) compared to group(s) with different Time Perspective Cross-sectional: observations or measurements made at a single point in time, usually at subject enrollment Biospecimen Retention - select one Samples Without DNA - samples retained, with no potential for DNA extraction from any retained samples (e.g., fixed tissue, plasma) Biospecimen Description
Sputum, whole blood, urine, tissue Enrollment
Single group study Number of Groups/Cohorts Definition: Number of study groups/cohorts. Enter 1 for a single-group study. Many observational studies have one group/cohort; case control studies typically have two.
One study group, anticipated samples in the rang of 400-500 samples 8. Arms, Groups and Interventions N/L Group/Cohort Label
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Eastern
-
Dammam, Eastern, Saudi Arabia, 31451
- King Faisal Univrsity, Departmentof Microbiology and Immunology,, dammam branh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients with infection with MDRs infections will be included
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Multidrug resistant (MDR)bacterial strains
|
Drug: In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance
studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals.
Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Asim E Ltayeb Diab, MD, Ph D, Assist. Professor and Consultant Microbiologist
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3074X1-4548
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections, Bacterial
-
Sir Run Run Shaw HospitalUniversity of BirminghamUnknown
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineWithdrawn
-
GlaxoSmithKlineWithdrawn
Clinical Trials on In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance
-
Taizhou HospitalFirst Affiliated Hospital of Zhejiang University; Taizhou First People's Hospital and other collaboratorsUnknown